![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ME3 |
Gene summary for ME3 |
![]() |
Gene information | Species | Human | Gene symbol | ME3 | Gene ID | 10873 |
Gene name | malic enzyme 3 | |
Gene Alias | NADP-ME | |
Cytomap | 11q14.2 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q16798 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10873 | ME3 | male-WTA | Human | Thyroid | PTC | 3.36e-07 | 1.03e-01 | 0.1037 |
10873 | ME3 | PTC01 | Human | Thyroid | PTC | 5.59e-05 | 7.20e-02 | 0.1899 |
10873 | ME3 | PTC04 | Human | Thyroid | PTC | 1.39e-05 | 1.22e-01 | 0.1927 |
10873 | ME3 | PTC06 | Human | Thyroid | PTC | 1.09e-09 | 3.08e-01 | 0.2057 |
10873 | ME3 | PTC07 | Human | Thyroid | PTC | 7.76e-10 | 1.49e-01 | 0.2044 |
10873 | ME3 | ATC09 | Human | Thyroid | ATC | 2.33e-04 | 3.04e-01 | 0.2871 |
10873 | ME3 | ATC12 | Human | Thyroid | ATC | 1.58e-03 | 1.02e-01 | 0.34 |
10873 | ME3 | ATC1 | Human | Thyroid | ATC | 1.57e-04 | 3.54e-01 | 0.2878 |
10873 | ME3 | ATC2 | Human | Thyroid | ATC | 1.12e-18 | 1.14e+00 | 0.34 |
10873 | ME3 | ATC4 | Human | Thyroid | ATC | 9.88e-04 | 1.40e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000920614 | Breast | IDC | purine ribonucleoside triphosphate biosynthetic process | 24/1434 | 68/18723 | 7.70e-11 | 1.07e-08 | 24 |
GO:000914514 | Breast | IDC | purine nucleoside triphosphate biosynthetic process | 24/1434 | 69/18723 | 1.10e-10 | 1.38e-08 | 24 |
GO:000914214 | Breast | IDC | nucleoside triphosphate biosynthetic process | 26/1434 | 85/18723 | 4.72e-10 | 5.06e-08 | 26 |
GO:000920113 | Breast | IDC | ribonucleoside triphosphate biosynthetic process | 24/1434 | 74/18723 | 5.73e-10 | 6.03e-08 | 24 |
GO:000914414 | Breast | IDC | purine nucleoside triphosphate metabolic process | 26/1434 | 88/18723 | 1.09e-09 | 1.07e-07 | 26 |
GO:000920514 | Breast | IDC | purine ribonucleoside triphosphate metabolic process | 25/1434 | 82/18723 | 1.10e-09 | 1.07e-07 | 25 |
GO:000914114 | Breast | IDC | nucleoside triphosphate metabolic process | 29/1434 | 112/18723 | 3.68e-09 | 3.03e-07 | 29 |
GO:000919913 | Breast | IDC | ribonucleoside triphosphate metabolic process | 25/1434 | 89/18723 | 7.22e-09 | 5.47e-07 | 25 |
GO:000915214 | Breast | IDC | purine ribonucleotide biosynthetic process | 34/1434 | 169/18723 | 1.63e-07 | 8.92e-06 | 34 |
GO:004639013 | Breast | IDC | ribose phosphate biosynthetic process | 36/1434 | 190/18723 | 3.40e-07 | 1.73e-05 | 36 |
GO:000926013 | Breast | IDC | ribonucleotide biosynthetic process | 35/1434 | 182/18723 | 3.40e-07 | 1.73e-05 | 35 |
GO:000915014 | Breast | IDC | purine ribonucleotide metabolic process | 55/1434 | 368/18723 | 1.30e-06 | 5.72e-05 | 55 |
GO:001969314 | Breast | IDC | ribose phosphate metabolic process | 58/1434 | 396/18723 | 1.31e-06 | 5.73e-05 | 58 |
GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
GO:000911713 | Breast | IDC | nucleotide metabolic process | 67/1434 | 489/18723 | 2.28e-06 | 9.05e-05 | 67 |
GO:000925914 | Breast | IDC | ribonucleotide metabolic process | 56/1434 | 385/18723 | 2.47e-06 | 9.63e-05 | 56 |
GO:000616413 | Breast | IDC | purine nucleotide biosynthetic process | 34/1434 | 191/18723 | 3.11e-06 | 1.15e-04 | 34 |
GO:190129313 | Breast | IDC | nucleoside phosphate biosynthetic process | 41/1434 | 256/18723 | 5.15e-06 | 1.73e-04 | 41 |
GO:000616314 | Breast | IDC | purine nucleotide metabolic process | 56/1434 | 396/18723 | 5.90e-06 | 1.90e-04 | 56 |
GO:004693913 | Breast | IDC | nucleotide phosphorylation | 22/1434 | 101/18723 | 6.31e-06 | 1.98e-04 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ME3 | SNV | Missense_Mutation | novel | c.1717G>A | p.Ala573Thr | p.A573T | Q16798 | protein_coding | tolerated(0.17) | benign(0.029) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ME3 | SNV | Missense_Mutation | novel | c.1797N>T | p.Met599Ile | p.M599I | Q16798 | protein_coding | tolerated(0.11) | benign(0.011) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ME3 | SNV | Missense_Mutation | novel | c.1147N>C | p.Asn383His | p.N383H | Q16798 | protein_coding | deleterious(0.05) | possibly_damaging(0.863) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ME3 | SNV | Missense_Mutation | novel | c.1112N>A | p.Ser371Tyr | p.S371Y | Q16798 | protein_coding | deleterious(0) | possibly_damaging(0.652) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ME3 | SNV | Missense_Mutation | novel | c.521N>A | p.Ser174Tyr | p.S174Y | Q16798 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ME3 | SNV | Missense_Mutation | novel | c.577G>T | p.Gly193Cys | p.G193C | Q16798 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ME3 | SNV | Missense_Mutation | novel | c.347N>A | p.Arg116Gln | p.R116Q | Q16798 | protein_coding | deleterious(0.02) | possibly_damaging(0.873) | TCGA-EY-A1GF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ME3 | SNV | Missense_Mutation | novel | c.368N>A | p.Arg123Gln | p.R123Q | Q16798 | protein_coding | deleterious(0.02) | possibly_damaging(0.613) | TCGA-DD-AAVY-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ME3 | SNV | Missense_Mutation | rs150824447 | c.421N>A | p.Val141Met | p.V141M | Q16798 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-50-5068-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | taxol | PD |
ME3 | SNV | Missense_Mutation | c.385N>T | p.Val129Leu | p.V129L | Q16798 | protein_coding | tolerated(0.07) | benign(0.106) | TCGA-50-5936-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10873 | ME3 | ENZYME | DHT | ANDROSTANOLONE | 1811987 | |
10873 | ME3 | ENZYME | ASPIRIN | ASPIRIN | 8611656 | |
10873 | ME3 | ENZYME | GLUTACONATE | GLUTACONATE | 19595601 | |
10873 | ME3 | ENZYME | MALEIC ACID | MALEIC ACID | 19595601 | |
10873 | ME3 | ENZYME | MALONIC ACID | MALONIC ACID | 19595601 |
Page: 1 |